Amgen Research (munich) Gmbh

Micromet Ag

Amgen Research Gmbh

Steven Zeman

Tobias Raum

Andreas Wolf

Sandra Bruckmaier

Peter Kufer

Birgit Kohleisen

Patrick Bäuerle

Julia Hepp (nee Henckel)

Eva Vieser (nee Krinner)

Silke Petsch (nee Mittelstrass)

Ralf Lutterbüse

Roman Kischel

Susanne Mangold

Ralf Lutterbuese

Christian Itin

Meera Berry

Eva Krinner

Eva Vieser

Silke Petsch

Julia Hepp

Patrick Baeuerle

Patrick Bauerle

Ralf LUTTERBÜSE

The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.

Antibody neutralizers of human granulocyte macrophage colony stimulating factor

The present invention provides a method for the preparation of a human binding molecule, fragment or derivative thereof which specifically binds to the human CD3 complex. Furthermore, the invention provides a human binding molecules specifically binding to the human CD3 complex and means comprising said human binding molecules.

Human-anti-human cd3 binding molecules

The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (V) and the corresponding variable light chain regions (V) regions are arranged, from N-terminus to C-terminus, in the order V(CD19)-V(CD19)-V(CD3)-V(CD3) or V(CD3)-V-(CD3)-V(CD19)-V(CD19). Processes for the production of the pharmaceutical compositions and medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are also disclosed.

Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders

Growing community of inventors

Pullad, Germany

Steven Zeman